Angiographic Delivery of AD-MSC for Ulcerative Colitis

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Ulcerative Colitis

Interventions

DRUG

Adipose derived, autologous mesenchymal stem cells

Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.

Trial Locations (1)

Mayo Clinic in Rochester, Rochester